



**Business in Space Growth Network** 

### LIFE SCIENCES INDUSTRY ACCELERATOR


**Space for Inspiration – Jan 2024** 



## MEDES — Institute for space physiology and medicine

**TYPES OF ACTIVITIES** 

- A hybrid organization for SPACE and HEALTH
- A multidisciplinary team with various health professionals & IT biomedical and space engineers
- Economic Group of Interest, main members: CNES et Toulouse Univ. Hospital



#### Common fields of innovation



Biotech, Pharma

MEDES



Digital Health, Connected Health Environment & health, teleepidemiology, public policies




## **BSGN Life Sciences Industry Accelerator**

Develop LEO-based commercial services addressing terrestrial Life Science and biomanufacturing challenges

- Bring Awareness of the Benefits of Space to the non-space community
- Build a Life Sciences community with commercial space providers and scientific/industrial partners

### **PROJECT MATURATION**

- Illustrate and demonstrate the potential of microgravity for industrial applications
- Identify projects for space experiments
- Support access to space



#### **FUNDING**

- Identify potential funding for space experiments and projects (ESA or non-ESA)
- Link with national delegates

- New terrestrial industrial needs and use cases for space commercialization
- Support maturation of space offers related to industry needs
- Help define standard requirements for equipment / infrastructure

#### **MODEL IDENTIFICATION**

- Network new models for cooperation and innovation to generate IP
- Help make space a usual research environment for pharma / biotech



# Market assessment on Life Sciences


# 1


### 2021-2022 : MARKET ASSESMENT / STAKEHOLDER EDUCATION AND ENGAGEMENT

CHALLENGES IN TERRESTRIAL	BIOMANUFATURING MARKET	LEO ASS	ETS FOR BIOMAN	UFACTURING MARKET	
NEW BIOMEDICINE To produce biomedicines with disruptive properties from new sources	SMALL VOLUME To produce complex proteins in (very) small volumes for personalized medicine	LIVING ( Changes in morphologica	<b>BEHAVIOR OF</b> <b>ORGANISMS</b> gene expression, I modifications and ellular physiology	ACCELERATED DISEASE MODEL Accelerated model of age related disorders	<ul> <li>1-1 meetings,</li> <li>Webinars,</li> </ul>
MANUFACTURING EFFICIENCY To improve the results of the entire manufacturing chain	<b>NEW MODEL</b> To develop suitable design tools to save considerable time and money	PROTEINS/CRYSTAL GROWTH Molecule crystals grow larger with fewer defects, new polymorphs and morphologies of crystals to be discovered		PHASE CHANGES FOR PROCESS Study of separation processes on both micro and macroscale	<ul><li>Workshops,</li><li>Events</li></ul>
FIVE LE	ADING TERRESTRIAL SEGMENT	'S BENEFITTING THE	MOST FROM MI	CROGRAVITY	
1r	SAL SAL	₩ ₩	Ē	(O) (O)	
ANTIBODIES	THERAPEUTICS MOLECULES & PROTEINS	GENE THERAPY	VACCINES	CELL THERAPIES	

# Selection of Project Portfolio

**2022-2023 : CALL FOR PROJECTS AND SELECTION OF THE FIRST PROJECT PORTFOLIO** 





- Space background from the neophyte to the expert level
- Maturity of the project from the initial idea up to "ready for flight"



# Current support of project portfolio



### 2023-2024 : PROJECTS MATURATION AND SUPPORT

BASIC SERVICES	DECISION GATE 1	<b>ADVANCED SERVICES</b>	DECISION GATE 2
<b>JULY</b> <b>2023</b> Inform, coach and challenge project	ts 🄶 T	Tailored individual coaching + ~ 60k€ co-fundin	
<ul> <li>1-1 meetings to discuss technical, commercial and business aspects</li> <li>Dedicated webinars (ex IP, regulations, working with ESA)</li> <li>Co-funding identification (ESA and non-ESA)</li> <li>Networking with space providers, potential partners, investors</li> <li>Communication, events, shared information</li> </ul>	Most mature projects with identified co- funding can sollicite DG1 to move forward to Advanced Acceleration Services	<ul> <li>Validate market vision, business model and technical aspects</li> <li>Build the experiment (expertise, payload design)</li> <li>Identify and apply to funding solutions relevant for each specific case to secure the financial architecture of each project for implementation (both ESA and non- ESA funding)</li> <li>Validate juridical framework (intellectual property, contractual pattern, market pathway)</li> </ul>	Projects with co-funding ready for implementation can solicit DG2 to move towards flight

ME

-5

## Where are we now?



#### 3 projects sollicited DG1 in December 2023

They are granted ~ 60k€ to continue to develop the project and get ready for implementation with flights envisioned end of 2024 or beginning of 2025.



Academic consortium led by the University of Milan Bicocca

**TOPIC:** Develop ground-breaking technology for Low-Earth-Orbit (LEO) structural characterization of nonnative protein pharmacological targets. Drug discovery and optimization thanks to structural information about the crystallization of proteins in microgravity conditions.



Start-up project from Prometheus Life Technologies

**TOPIC:** Standardized, large-scale commercial production of human organoids using the microgravity environment of space. Organoids to be used as models in preclinical drug testing or in general life sciences research and in regenerative medicine therapies HORUS

Public-Private consortium led by the University of Grenoble Alpes

**TOPIC:** Develop a therapeutical response prediction and target deciphering using AI driven image analysis and extraction.Build a tumoroid-avatar minilab" to be used at the bedside and use microgravity as a therapeutic tool to combat solid stress in brain tumors



# What is next?

- Keep supporting the projects in our portfolio
   We are expecting more projects to sollicit Decision Gate 1 in 2024
- Have first projects fly as soon as possible to build success stories
- Identify a durable framework for the Accelerator for future calls and support

### **THANK YOU FOR YOUR ATTENTION !**

